As we increase our radioligand therapy (RLT) manufacturing footprint, we are intentionally creating space for continued innovation and growth, driven by the opportunities these advancements may present for patients worldwide. #ReimagineMedicine
Today we announced the construction of two new radioligand therapy (RLT) manufacturing facilities, one of which will produce critical isotopes necessary to create these medicines. As the leader in RLT development and delivery, we remain committed to pioneering RLT science and broadening manufacturing capabilities to support the growing demand for this novel approach to cancer care.